I am a board-certified medical oncologist who is dedicated to improving the lives of patients with genitourinary tumors. My primary area of expertise is kidney cancer (renal cell carcinoma) and testicular cancer (germ-cell tumor). For more than 25 years, I have used my skills as a clinician to provide high-quality and compassionate care for cancer patients at Memorial Sloan Kettering.
In addition to providing patients with the highest standard of medical care, I have led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical trials. My research has helped to identify five targeted drugs — sunitinib (Sutent®), pazopanib (Votrient®), axitinib (Inlyta®), temsirolimus (Torisel®), and everolimus (Afinitor®) — as effective treatments for patients with advanced kidney cancer. Also, I developed a system to aid in the prediction of treatment outcomes for patients taking medications for advanced kidney cancer; this (“MSKCC”) risk system is widely applied by physicians internationally to direct the care of patients. In the area of testicular cancer, my patient care and research efforts focus on developing better treatments for patients with difficult-to-treat tumors.